2020

23.04.2020 – Zur Rose Group AG

2020 Annual General Meeting of Zur Rose Group AG: Shareholders adopt all proposals

Zur Rose Group AG / Key word(s): AGMEGM
2020 Annual General Meeting of Zur Rose Group AG: Shareholders adopt all
proposals

23.04.2020 / 18:00

---------------------------------------------------------------------------

Press release

2020 Annual General Meeting of Zur Rose Group AG

Shareholders adopt all proposals

The 27th Annual General Meeting of Shareholders of Zur Rose Group AG was
held today in Zurich. Owing to the exception circumstances related to the
coronavirus, the meeting took place without shareholders being physically
present. A total of 4,021,346 shareholder votes, equivalent to 41.7 per cent
of the share capital and 72.3 per cent of the shares entitled to vote, were
represented by the independent proxy. The Board of Directors would like to
thank all those who exercised their rights as shareholders in this way.

The shareholders approved the Management Report, the Annual Financial
Statements and Consolidated Financial Statements for 2019 and the
appropriation of retained earnings and ratified the actions taken by the
Board of Directors and Group Management during the year. The Chairman of the
Board of Directors, all members of the Board of Directors and all members of
the Compensation Committee were confirmed in office for a further term of
one year. The AGM approved the requested maximum amounts of compensation for
the members of the Board of Directors and Group Management for financial
years 2019, 2020 and 2021. The Compensation Report for financial year 2019
was also endorsed in a consultative vote. Ernst & Young AG were confirmed as
the statutory auditor and Fürer Partner Advocaten KIG as the independent
proxy for another term of one year.

Shareholders also approved the proposal to create authorised share capital
with a nominal value of CHF 26,219,910, equivalent to 10 per cent of the
registered share capital. As announced on 20 April 2020, the motion to
create additional conditional capital was withdrawn.

The minutes of the AGM (in German) with the detailed voting results are
available at "www.zurrosegroup.com > Investors & Media > General Meeting of
Shareholders" from 24 April 2020.

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Agenda
19 August 2020 Half-Year Results
21 October 2020 Q3 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of
the leading medical wholesalers in Switzerland. It also operates the leading
marketplace in southern Europe for consumer health, beauty and personal care
products commonly sold in pharmacies. The company is internationally present
with strong brands, including Germany's best-known pharmacy brand DocMorris.
Zur Rose employs more than 1,800 people at sites in Switzerland, Germany,
the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569
million (including medpex) and has around seven million active customers in
core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and
cost-effective pharmaceutical care. It is also characterized by the
continuous further development of digital services in the field of drug
management using AI-supported applications and new technology. Zur Rose is
furthermore actively driving ahead its positioning as a comprehensive
provider of healthcare services. By creating a digital healthcare platform -
the Zur Rose ecosystem - it networks products and digital services from
qualified providers. The contribution made by Zur Rose will be to take these
offerings to customers and patients and to make a relevant selection. The
aim is to provide people with a seamless accompaniment and empower them to
manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange
(securities number 4261528, ISIN CH0042615283, ticker ROSE). For further
information please see zurrosegroup.com.


close